Drug approval triggers debate on future direction for cancer treatments.
Frantz
Simon
S
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001557:Benzenesulfonates / Q000494:pharmacology / Q000627:therapeutic use; D017277:Drug Approval; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000494:pharmacology; D009369:Neoplasms / Q000188:drug therapy*; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D010770:Phosphotransferases / Q000037:antagonists & inhibitors; D011725:Pyridines / Q000494:pharmacology / Q000627:therapeutic use; D000077157:Sorafenib; D014481:United States; D014486:United States Food and Drug Administration
D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D004791:Enzyme Inhibitors; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib; D010770:Phosphotransferases